20.9 C
New York
Wednesday, July 28, 2021

Novartis immuno-oncology drug candidate fails skin cancer trial

Must read

XRP avança 10% em um rali

Cripto9 minutos atrás (28.07.2021 04:34) © Reuters. XRP avança 10% em um rali Investing.com - O XRP era negociado nesta quarta-feira a US$0,68693 às 04:32 (07:32 GMT) segundo o...

XRP Climbs 10% In Rally

Cryptocurrency10 minutes ago (Jul 28, 2021 03:33AM ET) (C) Reuters. XRP Climbs 10% In Rally Investing.com - XRP was trading at $0.68693 by 03:32 (07:32 GMT)...

Lloyd’s of London insurer Lancashire swings to H1 profit

Stock Markets13 minutes ago (Jul 28, 2021 03:30AM ET) (C) Reuters. (Corrects earnings forecast in para 1 and 7) LONDON (Reuters) -Lloyd's of London insurer...

CBDCs ‘concocted in hell by Satan himself’ says ASI president Rich Checkan

Sign In/Free Sign Up 0 Cryptocurrency23 minutes ago (Jul 28, 2021 03:20AM ET) CBDCs 'concocted in hell by Satan himself' says ASI president Rich...
imageStock Markets1 hour ago (Aug 22, 2020 03:20AM ET)

(C) Reuters. The logo of Swiss drugmaker Novartis is pictured at the French company’s headquarters in Rueil-Malmaison

ZURICH (Reuters) – Swiss drugmaker Novartis said on Saturday that its investigational spartalizumab immuno-oncology drug mixed with the approved medicines Tafinlar and Mekinist failed in a late-stage trial for a type of advanced skin cancer.

The drug did not improve progression-free survival in previously untreated patients with BRAF V600 mutation-positive cutaneous melanoma, compared to Tafinlar + Mekinist alone, Novartis said.

Despite the failure, Novartis is continuing development of spartalizumab, a so-called checkpoint inhibitor thought to help take the brakes off the immune system in fighting cancer, against other kind of tumors, the Basel-based company said.

Novartis has been late in developing such immuno-oncology drugs for its portfolio, a field now dominated by lucrative medicines including Merck’s Keytruda, Bristol-Myers Squibb (NYSE:BMY)’s Opdivo, and to a lesser extent, Roche’s Tecentriq.

Novartis immuno-oncology drug candidate fails skin cancer trial

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

- Advertisement -

Latest article

XRP avança 10% em um rali

Cripto9 minutos atrás (28.07.2021 04:34) © Reuters. XRP avança 10% em um rali Investing.com - O XRP era negociado nesta quarta-feira a US$0,68693 às 04:32 (07:32 GMT) segundo o...

XRP Climbs 10% In Rally

Cryptocurrency10 minutes ago (Jul 28, 2021 03:33AM ET) (C) Reuters. XRP Climbs 10% In Rally Investing.com - XRP was trading at $0.68693 by 03:32 (07:32 GMT)...

Lloyd’s of London insurer Lancashire swings to H1 profit

Stock Markets13 minutes ago (Jul 28, 2021 03:30AM ET) (C) Reuters. (Corrects earnings forecast in para 1 and 7) LONDON (Reuters) -Lloyd's of London insurer...

CBDCs ‘concocted in hell by Satan himself’ says ASI president Rich Checkan

Sign In/Free Sign Up 0 Cryptocurrency23 minutes ago (Jul 28, 2021 03:20AM ET) CBDCs 'concocted in hell by Satan himself' says ASI president Rich...

Santander profit beats forecasts on strong U.S. and UK markets

Stock Markets28 minutes ago (Jul 28, 2021 03:15AM ET) (C) Reuters. FILE PHOTO: Banco Santander's boss Ana Patricia Botin speaks during the annual results presentation...